PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 9624173-9 1998 Finally, using cycloheximide induction to examine mRNA half-lives, we show that mRNA turnover is increased sufficiently by mechanisms targeting the exon 2 and 3 regulatory elements to account for the magnitude of c-myc mRNA down-regulation during differentiation. Cycloheximide 15-28 MYC proto-oncogene, bHLH transcription factor Homo sapiens 213-218 10891489-7 2000 HMG-I/Y expression is stimulated by c-Myc in a Myc-estradiol receptor cell line in the presence of the protein synthesis inhibitor cycloheximide, indicating that HMG-I/Y is a direct c-Myc target gene. Cycloheximide 131-144 MYC proto-oncogene, bHLH transcription factor Homo sapiens 182-187 9369245-1 1997 Cycloheximide in sublethal doses caused apoptosis in liver cells in vivo, inducing c-myc, c-fos, c-jun and p53 genes and accumulation of sphingosine, a toxic product of the sphingomyelin cycle. Cycloheximide 0-13 MYC proto-oncogene, bHLH transcription factor Homo sapiens 83-88 8799562-15 1996 Tranilast still had an inhibitory effect on the induction of c-myc mRNA when de novo protein synthesis was inhibited by cycloheximide and did not shorten the degradation of c-myc mRNA at the post-transcriptional level, demonstrating that tranilast directly inhibited c-myc mRNA expression at the transcriptional level. Cycloheximide 120-133 MYC proto-oncogene, bHLH transcription factor Homo sapiens 61-66 8695842-3 1996 In M1mycer cells, when endogenous c-myc expression has been suppressed following stimulation by interleukin-6 (IL-60), treatment with estrogen and cycloheximide results in induction of ODC transcripts. Cycloheximide 147-160 MYC proto-oncogene, bHLH transcription factor Homo sapiens 34-39 8142255-7 1994 When cycloheximide was present during the first 36 h priming period of dexamethasone treatment, there was an immediate loss of c-myc protein and apoptosis at 54 h was completely inhibited. Cycloheximide 5-18 MYC proto-oncogene, bHLH transcription factor Homo sapiens 127-132 8778231-8 1996 Incubation with cycloheximide or 10% fetal calf serum increased c-myc mRNA levels 3- and 4-fold respectively. Cycloheximide 16-29 MYC proto-oncogene, bHLH transcription factor Homo sapiens 64-69 8572166-8 1995 In contrast to blocking NCX induction, cycloheximide potentiated c-Myc induction by serum. Cycloheximide 39-52 MYC proto-oncogene, bHLH transcription factor Homo sapiens 65-70 7623834-6 1995 Moreover, we show that in the liver, c-myc exon 2 sequences are able to down-regulate an otherwise stable H-2K mRNA when embedded within it and to induce its transient accumulation after cycloheximide treatment and soon after liver ablation. Cycloheximide 187-200 MYC proto-oncogene, bHLH transcription factor Homo sapiens 37-42 8065303-4 1994 On the other hand, there was a dramatic increase in c-Myc mRNA expression in TNF-alpha-sensitive D98 cells, but not in TNF-alpha-resistant H21 cells, which was only observed when the cells were treated with cycloheximide. Cycloheximide 207-220 MYC proto-oncogene, bHLH transcription factor Homo sapiens 52-57 8325387-6 1993 Cycloheximide blocks butyrate-dependent reduction of c-myc mRNA levels. Cycloheximide 0-13 MYC proto-oncogene, bHLH transcription factor Homo sapiens 53-58 8190258-4 1994 In the guinea-pig enteric nervous system, c-Myc-like immunoreactivity detected by two different antibodies remained detectable for up to 4 h in the presence of cycloheximide. Cycloheximide 160-173 MYC proto-oncogene, bHLH transcription factor Homo sapiens 42-47 8439572-6 1993 Cycloheximide reversed the instability induced by 1,25(OH)2D3, prolonging the half-life of c-myc mRNA in both uninduced and 1,25(OH)2D3-induced HL-60 cells to > 60 min, indicating a translational requirement for the destabilization process. Cycloheximide 0-13 MYC proto-oncogene, bHLH transcription factor Homo sapiens 91-96 1995415-6 1991 We find that induction by cycloheximide is due to stabilization of c-myc transcripts. Cycloheximide 26-39 MYC proto-oncogene, bHLH transcription factor Homo sapiens 67-72 8225910-0 1993 Effect of gamma-interferon or cycloheximide treatment on viral and c-myc transcripts in bovine-papillomavirus-type-1-transformed primary mouse fibroblasts. Cycloheximide 30-43 MYC proto-oncogene, bHLH transcription factor Homo sapiens 67-72 8225910-6 1993 Cycloheximide treatment increased both viral and c-myc gene transcripts 3- to 20-fold in all cell lines. Cycloheximide 0-13 MYC proto-oncogene, bHLH transcription factor Homo sapiens 49-54 2048200-5 1991 Inhibition of protein synthesis with cycloheximide during IFN-alpha or CsA treatment blocked their ability to reduce the expression of c-myc. Cycloheximide 37-50 MYC proto-oncogene, bHLH transcription factor Homo sapiens 135-140 1593910-11 1992 In contrast, c-myc was expressed at high levels in UCSD/AML1 cells and showed evidence for specific regulation in response to cycloheximide, phorbol ester, and GM-CSF withdrawal and restimulation. Cycloheximide 126-139 MYC proto-oncogene, bHLH transcription factor Homo sapiens 13-18 1995415-7 1991 The requirements for increased expression of c-myc mRNA by cycloheximide are the presence of the sequence encoding c-myc amino acids 335-439 on a mRNA that can be translated; all other portions of the c-myc gene are dispensable, and this sequence can confer induction of mRNA expression by protein synthesis inhibitors on a heterologous gene. Cycloheximide 59-72 MYC proto-oncogene, bHLH transcription factor Homo sapiens 45-50 1995415-7 1991 The requirements for increased expression of c-myc mRNA by cycloheximide are the presence of the sequence encoding c-myc amino acids 335-439 on a mRNA that can be translated; all other portions of the c-myc gene are dispensable, and this sequence can confer induction of mRNA expression by protein synthesis inhibitors on a heterologous gene. Cycloheximide 59-72 MYC proto-oncogene, bHLH transcription factor Homo sapiens 115-120 1995415-7 1991 The requirements for increased expression of c-myc mRNA by cycloheximide are the presence of the sequence encoding c-myc amino acids 335-439 on a mRNA that can be translated; all other portions of the c-myc gene are dispensable, and this sequence can confer induction of mRNA expression by protein synthesis inhibitors on a heterologous gene. Cycloheximide 59-72 MYC proto-oncogene, bHLH transcription factor Homo sapiens 115-120 34646892-8 2021 Stability of the c-Myc protein was measured using cycloheximide. Cycloheximide 50-63 MYC proto-oncogene, bHLH transcription factor Homo sapiens 17-22 2111449-6 1990 However, the mRNA from both genes increased markedly after cycloheximide injection, suggesting that the regulation of c-myc mRNA abundance in the regenerating liver differs from that occurring after protein synthesis inhibition. Cycloheximide 59-72 MYC proto-oncogene, bHLH transcription factor Homo sapiens 118-123 1900228-8 1991 The usefulness of the technique was further examined following treatment of exponentially growing HL-60 cells with 2.5 micrograms/ml cycloheximide for 0 to 12 h. Cycloheximide treatment was found to cause a significant decrease in c-myc oncoprotein content within 2 h (P less than 0.05), a relative increase in the proportion of G0/G1 cells and a modest decrease in total cellular protein. Cycloheximide 133-146 MYC proto-oncogene, bHLH transcription factor Homo sapiens 231-236 1900228-8 1991 The usefulness of the technique was further examined following treatment of exponentially growing HL-60 cells with 2.5 micrograms/ml cycloheximide for 0 to 12 h. Cycloheximide treatment was found to cause a significant decrease in c-myc oncoprotein content within 2 h (P less than 0.05), a relative increase in the proportion of G0/G1 cells and a modest decrease in total cellular protein. Cycloheximide 162-175 MYC proto-oncogene, bHLH transcription factor Homo sapiens 231-236 2320412-6 1990 Furthermore, cycloheximide was able to overcome completely the dexamethasone-induced down-regulation of the c-myc gene expression. Cycloheximide 13-26 MYC proto-oncogene, bHLH transcription factor Homo sapiens 108-113 34088288-8 2021 Cycloheximide chase analysis was used to determine the c-Myc protein half-lives before and after matrine treatment. Cycloheximide 0-13 MYC proto-oncogene, bHLH transcription factor Homo sapiens 55-60 2551669-8 1989 Expression of the translocated c-myc alleles was also affected by TPA; however, only if cycloheximide was simultaneously present. Cycloheximide 88-101 MYC proto-oncogene, bHLH transcription factor Homo sapiens 31-36 2551669-9 1989 TPA plus cycloheximide induced a rapid decrease of c-myc RNA derived from the translocated allele within 6 h, whereas cycloheximide alone led to abolition of c-myc RNA after 16-24 h. This rapid decline of c-myc RNA was observed in Raji and BL41 cells, but not in three cell lines with variant t(2;8) and t(8;22) translocations. Cycloheximide 9-22 MYC proto-oncogene, bHLH transcription factor Homo sapiens 51-56 2551669-9 1989 TPA plus cycloheximide induced a rapid decrease of c-myc RNA derived from the translocated allele within 6 h, whereas cycloheximide alone led to abolition of c-myc RNA after 16-24 h. This rapid decline of c-myc RNA was observed in Raji and BL41 cells, but not in three cell lines with variant t(2;8) and t(8;22) translocations. Cycloheximide 118-131 MYC proto-oncogene, bHLH transcription factor Homo sapiens 158-163 2551669-9 1989 TPA plus cycloheximide induced a rapid decrease of c-myc RNA derived from the translocated allele within 6 h, whereas cycloheximide alone led to abolition of c-myc RNA after 16-24 h. This rapid decline of c-myc RNA was observed in Raji and BL41 cells, but not in three cell lines with variant t(2;8) and t(8;22) translocations. Cycloheximide 118-131 MYC proto-oncogene, bHLH transcription factor Homo sapiens 158-163 3285298-2 1988 Treatment with cycloheximide also causes a transient increase in the c-H-ras, c-myc and RaLV RNAs, with a time course similar to that obtained with UV irradiation. Cycloheximide 15-28 MYC proto-oncogene, bHLH transcription factor Homo sapiens 78-83 3290209-5 1988 MCF-7 nuclear runon assays show that c-myc transcription rates remain unchanged from base line for 24 h after E2 administration; as well, cycloheximide inhibition of protein synthesis superinduces c-myc expression and prevents E2 modulation of transcript levels. Cycloheximide 138-151 MYC proto-oncogene, bHLH transcription factor Homo sapiens 197-202 3034414-8 1987 However, cycloheximide treatment does exert a posttranscriptional effect involving the specific stabilization of the c-myc message. Cycloheximide 9-22 MYC proto-oncogene, bHLH transcription factor Homo sapiens 117-122 3497923-4 1987 A similar rapid increase in c-fos and c-myc mRNA was seen in quiescent FS-4 cells exposed to cycloheximide. Cycloheximide 93-106 MYC proto-oncogene, bHLH transcription factor Homo sapiens 38-43 3497813-7 1987 Both c-fos and c-myc mRNA expression were super-induced by the addition of cycloheximide. Cycloheximide 75-88 MYC proto-oncogene, bHLH transcription factor Homo sapiens 15-20 3295065-4 1987 The c-myc RNA reduction was also detected in cells whose protein synthesis was inhibited by more than 95% with cycloheximide or emetine. Cycloheximide 111-124 MYC proto-oncogene, bHLH transcription factor Homo sapiens 4-9 4062932-4 1985 Previous results in the literature have shown that 2 other oncogenes, c-myc and c-fos, can be induced by growth factors in the presence of cycloheximide. Cycloheximide 139-152 MYC proto-oncogene, bHLH transcription factor Homo sapiens 70-75 3754873-6 1986 When induction of differentiation in responsive cells was delayed by cycloheximide, a temporal correlation could be made between changes in the expression of the c-myc gene and differentiation. Cycloheximide 69-82 MYC proto-oncogene, bHLH transcription factor Homo sapiens 162-167 2419474-11 1986 The subsequent downregulation of lymphokine and c-myc mRNAs was retarded by cycloheximide. Cycloheximide 76-89 MYC proto-oncogene, bHLH transcription factor Homo sapiens 48-53 2414665-11 1985 In agreement with this interpretation, we detected myc RNA as stable transcripts in differentiated F9 cells after treatment of the cells with cycloheximide. Cycloheximide 142-155 MYC proto-oncogene, bHLH transcription factor Homo sapiens 51-54 3012540-8 1986 Addition of the protein synthesis inhibitor cycloheximide, before the addition of PHA to cultures, abolished the PHA-induced accumulation of mRNAs for c-myb, N-ras, and TFR, but not of mRNAs for c-fos, c-myc, IL2, and IL2R. Cycloheximide 44-57 MYC proto-oncogene, bHLH transcription factor Homo sapiens 202-207 2999973-5 1985 Further, the results demonstrate that the increase in intracellular concentration of c-myc RNA induced by cycloheximide treatment of normal cells is the result of stabilization of this message. Cycloheximide 106-119 MYC proto-oncogene, bHLH transcription factor Homo sapiens 85-90 12080469-5 2002 However, in combination with tumor necrosis factor-alpha (TNF-alpha), cycloheximide efficiently increases steady-state levels of c-myc, suggesting that selective stress conditions are required to increase c-myc protein stability. Cycloheximide 70-83 MYC proto-oncogene, bHLH transcription factor Homo sapiens 129-134 4039726-4 1985 In contrast, mRNA of the oncogene product c-myc can be induced for a brief period immediately following serum starvation in the presence and absence of PMA, and in the presence of cycloheximide. Cycloheximide 180-193 MYC proto-oncogene, bHLH transcription factor Homo sapiens 42-47 32487733-6 2020 Cycloheximide chase assay revealed that EMD significantly shortened c-Myc half-life by approximately two-fold. Cycloheximide 0-13 MYC proto-oncogene, bHLH transcription factor Homo sapiens 68-73 18455888-9 2008 However, the presence of the protein synthesis inhibitor cycloheximide could reverse the repression of Myc, indicating the indirect repression of human NDRG1 by Myc. Cycloheximide 57-70 MYC proto-oncogene, bHLH transcription factor Homo sapiens 103-106 18455888-9 2008 However, the presence of the protein synthesis inhibitor cycloheximide could reverse the repression of Myc, indicating the indirect repression of human NDRG1 by Myc. Cycloheximide 57-70 MYC proto-oncogene, bHLH transcription factor Homo sapiens 161-164 6606489-4 1983 This induction of c-myc mRNA occurs in the presence of cycloheximide and, therefore, does not require the synthesis of new protein species. Cycloheximide 55-68 MYC proto-oncogene, bHLH transcription factor Homo sapiens 18-23 6606489-6 1983 In addition, c-myc mRNA is "superinduced" by the combination of cycloheximide and mitogen, a finding consistent with a model that a labile protein may regulate c-myc levels in these cells. Cycloheximide 64-77 MYC proto-oncogene, bHLH transcription factor Homo sapiens 13-18 6606489-6 1983 In addition, c-myc mRNA is "superinduced" by the combination of cycloheximide and mitogen, a finding consistent with a model that a labile protein may regulate c-myc levels in these cells. Cycloheximide 64-77 MYC proto-oncogene, bHLH transcription factor Homo sapiens 160-165 33461590-6 2021 The turnover of c-Myc variants was determined by degradation in presence of cycloheximide and by optical pulse-chase experiments.. Immunofluorescence of mouse prostate tissue and bioinformatics of human datasets were applied to correlate IKKalpha- and c-Myc levels. Cycloheximide 76-89 MYC proto-oncogene, bHLH transcription factor Homo sapiens 16-21 31694585-14 2019 In addition, a cycloheximide chase experiment showed that PRMT5 post-translationally regulated MYC stability. Cycloheximide 15-28 MYC proto-oncogene, bHLH transcription factor Homo sapiens 95-98 30226440-5 2018 METHODS: The phenotypic effects of MLN8237 in thyroid cancer cells were evaluated through a series of in vitro and in vivo experiments, and the mechanism of c-Myc affecting MLN8237 response were explored using Western blot, ubiquitination, and cycloheximide chase assays. Cycloheximide 244-257 MYC proto-oncogene, bHLH transcription factor Homo sapiens 157-162 17974960-3 2007 Here, we investigated whether induction of c-Myc by OA or protein synthesis inhibitor cycloheximide contributed to HBC growth inhibition and the mechanisms involved. Cycloheximide 86-99 MYC proto-oncogene, bHLH transcription factor Homo sapiens 43-48 17974960-5 2007 However, OA or cycloheximide treatments over 6 or 10 h, respectively, induced c-Myc expression. Cycloheximide 15-28 MYC proto-oncogene, bHLH transcription factor Homo sapiens 78-83 17974960-6 2007 Depletion of c-Myc, on the other hand, resulted in enhanced HBC cell viabilities when exposed to OA or cycloheximide, but not by Taxol. Cycloheximide 103-116 MYC proto-oncogene, bHLH transcription factor Homo sapiens 13-18 12080469-5 2002 However, in combination with tumor necrosis factor-alpha (TNF-alpha), cycloheximide efficiently increases steady-state levels of c-myc, suggesting that selective stress conditions are required to increase c-myc protein stability. Cycloheximide 70-83 MYC proto-oncogene, bHLH transcription factor Homo sapiens 205-210 11509750-6 2001 Cycloheximide elicited a dose-dependent increase in c-myc mRNA levels in NHBE and A549 cells, but did not alter expression of the housekeeping gene beta-actin. Cycloheximide 0-13 MYC proto-oncogene, bHLH transcription factor Homo sapiens 52-57